JP2007504235A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504235A5
JP2007504235A5 JP2006525396A JP2006525396A JP2007504235A5 JP 2007504235 A5 JP2007504235 A5 JP 2007504235A5 JP 2006525396 A JP2006525396 A JP 2006525396A JP 2006525396 A JP2006525396 A JP 2006525396A JP 2007504235 A5 JP2007504235 A5 JP 2007504235A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heteroarylalkyl
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006525396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504235A (ja
JP4842817B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/028308 external-priority patent/WO2005023815A2/en
Publication of JP2007504235A publication Critical patent/JP2007504235A/ja
Publication of JP2007504235A5 publication Critical patent/JP2007504235A5/ja
Application granted granted Critical
Publication of JP4842817B2 publication Critical patent/JP4842817B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006525396A 2003-09-03 2004-08-31 神経保護二環式化合物およびその使用方法 Expired - Lifetime JP4842817B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49995603P 2003-09-03 2003-09-03
US60/499,956 2003-09-03
PCT/US2004/028308 WO2005023815A2 (en) 2003-09-03 2004-08-31 Neuroprotective bicyclic compounds and methods for their use

Publications (3)

Publication Number Publication Date
JP2007504235A JP2007504235A (ja) 2007-03-01
JP2007504235A5 true JP2007504235A5 (enExample) 2007-10-04
JP4842817B2 JP4842817B2 (ja) 2011-12-21

Family

ID=34272894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525396A Expired - Lifetime JP4842817B2 (ja) 2003-09-03 2004-08-31 神経保護二環式化合物およびその使用方法

Country Status (9)

Country Link
US (2) US8067425B2 (enExample)
EP (1) EP1664050B1 (enExample)
JP (1) JP4842817B2 (enExample)
DK (1) DK1664050T3 (enExample)
ES (1) ES2564803T3 (enExample)
HU (1) HUE028528T2 (enExample)
PL (1) PL1664050T3 (enExample)
SI (1) SI1664050T1 (enExample)
WO (1) WO2005023815A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101632669B (zh) 2000-08-04 2011-05-18 Dmi生物科学公司 二酮基哌嗪和包含它们的组合物的使用方法
WO2004084809A2 (en) * 2003-03-20 2004-10-07 Neuren Pharmaceuticals Ltd. Neuroprotective macrocylic compounds and methods for their use
CN101947306B (zh) 2003-05-15 2014-06-18 安皮奥制药股份有限公司 T-细胞介导的疾病的治疗
US8791117B2 (en) * 2003-09-03 2014-07-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
WO2008063311A2 (en) * 2006-10-11 2008-05-29 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
EP2300011A4 (en) 2008-05-27 2012-06-20 Dmi Life Sciences Inc THERAPEUTIC PROCESSES AND COMPOUNDS
US9891219B2 (en) * 2008-10-10 2018-02-13 Mayo Foundation For Medical Education And Research Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
US7928233B2 (en) * 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
WO2011037644A1 (en) * 2009-09-25 2011-03-31 Neuren Pharmaceuticals Limited Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy
JP2013537195A (ja) 2010-09-07 2013-09-30 ディエムアイ アクイジション コーポレイション 疾患の治療
EP3721884A1 (en) 2011-10-10 2020-10-14 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease with da-dkp (= aspartyl-alanyl diketopiperazine)
AU2012323320B2 (en) 2011-10-10 2017-05-11 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
EA201490737A1 (ru) 2011-10-28 2014-09-30 Ампио Фармасьютикалз, Инк. Лечение ринита
CN108440571B (zh) * 2012-10-22 2022-11-04 希望之城 Etp衍生物
SG10201707619RA (en) 2013-03-15 2017-10-30 Ampio Pharmaceuticals Inc Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
DK3024463T3 (da) 2013-07-25 2020-06-29 Neuren Pharmaceuticals Ltd Neuroprotektive bicykliske forbindelser og fremgangsmåder til deres anvendelse til behandling af autismespektrumforstyrrelser og neurodevelopmentale forstyrrelser
EP3183240A4 (en) 2014-08-18 2018-06-27 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
HK1246669A1 (zh) 2015-06-22 2018-09-14 Ampio Pharmaceuticals, Inc. 人血清白蛋白低分子量组分在疾病治疗中的应用
KR20240155382A (ko) 2016-05-26 2024-10-28 가부시키가이샤 아미노 압 수면 개선제
US10822353B2 (en) 2016-09-15 2020-11-03 City Of Hope Dithio ETP derivatives
CN119112885A (zh) * 2018-03-16 2024-12-13 脑科学香料株式会社 缺氧障碍、缺血再灌注障碍或炎症的预防或治疗剂,移植用细胞保护剂,及生物体防腐剂
GB202015788D0 (en) * 2018-05-15 2020-11-18 Tran Lloyd Hung Loi Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders
AU2020369431A1 (en) 2019-10-22 2022-06-09 Neuren Pharmaceuticals Limited Bicyclic compounds and methods for their use in treating Pitt Hopkins Syndrome
WO2022173315A1 (en) * 2021-02-12 2022-08-18 Neuren Pharmaceuticals Limited Treatments of prader-willi syndrome
BE1032058B1 (nl) * 2023-10-26 2025-10-02 Rousselot Bv Cyclische analoog van glycine-proline voor gebruik bij de preventie en/of behandeling van fibrose

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469006A (de) * 1965-07-07 1969-02-28 Sandoz Ag Verfahren zur Herstellung neuer synthetischer Alkaloide
FI941826A7 (fi) * 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
US7202279B1 (en) 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
WO2003039487A2 (en) * 2001-11-09 2003-05-15 Neuronz Limited Cyclo(prolyl-glycine) and methods of use to treat neural disorders
WO2003041655A2 (en) * 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
WO2004084809A2 (en) * 2003-03-20 2004-10-07 Neuren Pharmaceuticals Ltd. Neuroprotective macrocylic compounds and methods for their use

Similar Documents

Publication Publication Date Title
JP2007504235A5 (enExample)
JP2020169171A5 (enExample)
JP2019537599A5 (enExample)
JP2015532295A5 (enExample)
JP2005523922A5 (enExample)
JP2017537940A5 (enExample)
JP2010510237A5 (enExample)
JP2007520440A5 (enExample)
JP2009535307A5 (enExample)
JP2020532547A5 (enExample)
JP2020512337A5 (enExample)
JP2016518437A5 (enExample)
JP2010526146A5 (enExample)
JP2008505157A5 (enExample)
JP2005530811A5 (enExample)
JP2006509749A5 (enExample)
JP2007520452A5 (enExample)
JP2020128426A5 (enExample)
JP2020505354A5 (enExample)
JP2020511450A5 (enExample)
JP2019520344A5 (enExample)
JP2019519593A5 (enExample)
JP2020511536A5 (enExample)
JP2007538031A5 (enExample)
JP2007515467A5 (enExample)